{
    "organizations": [],
    "uuid": "4c513f7926ab9151d8bdf76b1ada461bcbb4569b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-johnson-johnson-reports-2017-q4-lo/brief-johnson-johnson-reports-2017-q4-loss-of-3-99-per-share-idUSASB0C1UC",
    "ord_in_thread": 0,
    "title": "BRIEF-Johnson & Johnson Reports 2017 Q4 Loss Of $3.99 Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 23, 2018 / 11:52 AM / in 10 minutes BRIEF-Johnson & Johnson Reports 2017 Q4 Loss Of $3.99 Per Share Reuters Staff \nJan 23 (Reuters) - Johnson & Johnson: * REPORTS 2017 FOURTH-QUARTER RESULTS: * SEES FY 2018 ADJUSTED EARNINGS PER SHARE $8.00 TO $8.20 * SEES FY 2018 SALES $80.6 BILLION TO $81.4 BILLION * SEES FY 2018 SALES UP 3.5 TO 4.5 PERCENT \n* J&J - 2017 FOURTH-QUARTER SALES OF $20.2 BILLION INCREASED 11.5%; EPS WAS A LOSS OF $3.99 \n* Q4 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $20.07 BILLION -- THOMSON REUTERS I/B/E/S * J&J - ADJUSTED 2017 FOURTH-QUARTER EPS WAS $1.74 \n* J&J - ‍​ COMPANY RECORDS SPECIAL ITEM CHARGE OF APPROXIMATELY $13.6 BILLION RELATED TO RECENTLY ENACTED TAX LEGISLATION \n* J&J - EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON OPERATIONAL BASIS, WORLDWIDE SALES FOR Q4 INCREASED 4.2% \n* Q4 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $20.07 BILLION -- THOMSON REUTERS I/B/E/S \n* J&J - QTRLY WORLDWIDE CONSUMER SALES OF $3,540 MILLION VERSUS $3,432 MILLION \n* J&J QTRLY WORLDWIDE VELCADE SALES $271 MILLION VERSUS $273 MILLION IN Q3 2017 \n* J&J - QTRLY WORLDWIDE PHARMACEUTICAL SALES OF $9,681 MILLION VERSUS $8,232 MILLION \n* J&J - EXCLUDING NET IMPACT OF ACQUISITIONS, DIVESTITURES, ON OPERATIONAL BASIS, DOMESTIC SALES ROSE 4.1% AND INTERNATIONAL SALES ROSE 4.3% IN QUARTER \n* FY2018 EARNINGS PER SHARE VIEW $7.87, REVENUE VIEW $80.70 BILLION -- THOMSON REUTERS I/B/E/S \n* J&J QTRLY WORLDWIDE ZYTIGA SALES $755 MILLION VERSUS $669 MILLION IN Q3 2017 \n* J&J - QTRLY WORLDWIDE MEDICAL DEVICES SALES OF $6,974 MILLION VERSUS $6,442 MILLION \n* J&J QTRLY WORLDWIDE REMICADE SALES $1,466 MILLION VERSUS $1,647 MILLION IN Q3 \n* J&J QTRLY WORLDWIDE INVOKANA/INVOKAMET SALES $267 MILLION VERSUS $265 MILLION IN Q3 2017 Source text for Eikon: Further company coverage:",
    "published": "2018-01-23T13:52:00.000+02:00",
    "crawled": "2018-01-23T14:08:25.081+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "minute",
        "johnson",
        "report",
        "q4",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "johnson",
        "johnson",
        "report",
        "result",
        "see",
        "fy",
        "adjusted",
        "earnings",
        "per",
        "share",
        "see",
        "fy",
        "sale",
        "billion",
        "billion",
        "see",
        "fy",
        "sale",
        "percent",
        "j",
        "j",
        "sale",
        "billion",
        "increased",
        "eps",
        "loss",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "billion",
        "thomson",
        "reuters",
        "j",
        "j",
        "adjusted",
        "eps",
        "j",
        "j",
        "company",
        "record",
        "special",
        "item",
        "charge",
        "approximately",
        "billion",
        "related",
        "recently",
        "enacted",
        "tax",
        "legislation",
        "j",
        "j",
        "excluding",
        "net",
        "impact",
        "acquisition",
        "divestiture",
        "operational",
        "basis",
        "worldwide",
        "sale",
        "q4",
        "increased",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "billion",
        "thomson",
        "reuters",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "consumer",
        "sale",
        "million",
        "versus",
        "million",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "velcade",
        "sale",
        "million",
        "versus",
        "million",
        "q3",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "pharmaceutical",
        "sale",
        "million",
        "versus",
        "million",
        "j",
        "j",
        "excluding",
        "net",
        "impact",
        "acquisition",
        "divestiture",
        "operational",
        "basis",
        "domestic",
        "sale",
        "rose",
        "international",
        "sale",
        "rose",
        "quarter",
        "fy2018",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "billion",
        "thomson",
        "reuters",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "zytiga",
        "sale",
        "million",
        "versus",
        "million",
        "q3",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "medical",
        "device",
        "sale",
        "million",
        "versus",
        "million",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "remicade",
        "sale",
        "million",
        "versus",
        "million",
        "q3",
        "j",
        "j",
        "qtrly",
        "worldwide",
        "sale",
        "million",
        "versus",
        "million",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}